Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The new approval of Wegovy™ is for a current medication, semaglutide, but more than doubling the standard dose for diabetes treatment.
Read More »Doubling the Dose of Semaglutide for Weight Loss Approved
Tirzepatide Outperforms Insulin Glargine in HbA1c and Weight Loss
SURPASS-4 is a randomized controlled trial of tirzepatide once a week vs. insulin glargine once a day in type 2 diabetes patients with high cardiovascular risk.
Read More »Tirzepatide a Potential Drug for Weight Loss
Novel dual GIP and GLP-1 receptor agonist showed promising results for both reduction in A1C and weight loss.
Read More »Doubling the Semaglutide Dose Improves Weight Loss
Lifestyle management and intervention alongside a once-weekly semaglutide dose of 2.4 mg. can lead to improved weight loss for patients with overweight or obesity.
Read More »New Weight Loss Combo
A combined pharmacological therapy showed efficacy in bodyweight reduction without lifestyle, diet, physical activity changes or surgery.
Read More »Benefits of GLP1 RA and SGLT-2 Inhibitors in Type 2 Patients
GLP1 RA and SGLT-2 were compared to evaluate coronary health disease reduction in patients with type 2 diabetes.
Read More »Using Glucagon-like Peptide 1 Receptor Agonists In Type 1 Diabetes
Examining the effects of GLP-1RAs exenatide and liraglutide on weight and insulin dosage for type 1 diabetes patients.
Read More »Effects of Tirzepatide on Patients with Type 2 Diabetes Metabolic Profile
Tirzepatide is both a GIP and GLP-1 receptor agonist.
Read More »Using Semaglutide and Liraglutide To Protect the Kidney?
A two-for-one deal: both cardiovascular benefits and renal protection.
Read More »Common Diabetes Medication as Treatment for Parkinson’s Disease
Findings show Parkinson’s disease risk is reduced in patients with type 2 diabetes mellitus (T2DM) after treatment with exenatide.
Read More »